We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11,268.00 | 11,222.00 | 11,226.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.33 | 174.68B |
From Apr 2019 to Apr 2024
TIDMAZN
RNS Number : 8849R
AstraZeneca PLC
05 March 2019
5 March 2019 11:00 GMT
ANNUAL FINANCIAL REPORT
AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2018 (Annual Report).
A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
The Annual Report is also available on the Company's website at www.astrazeneca.com/annualreport2018.
The Annual Report will be dispatched to shareholders in due course.
The Company's Annual General Meeting (AGM) will take place on 26 April 2019 in London, UK and the Notice of AGM and Shareholders' Circular will be published and distributed to shareholders in due course.
EXPLANATORY NOTE AND WARNING
Solely for the purposes of complying with Disclosure and Transparency Rule (DTR) 6.3.5R and the requirements it imposes on issuers as to how to make public annual financial reports, we set out below:
- in Appendix A, the principal risks and uncertainties facing the Company;
- in Appendix B, the Directors' responsibility statement made in respect of the Financial Statements and Directors' Report contained in the Annual Report; and
- in Appendix C, a statement regarding related party transactions.
The appendices have been extracted from the Annual Report in unedited full text. This information should be read in conjunction with the Company's fourth quarter and full year results 2018 announcement, issued on 14 February 2019, which contained a condensed set of financial statements and which can be found at www.astrazeneca.com/investor-relations/results-and-presentations.html. Together, these constitute the material required by DTR 6.3.5R to be communicated to the media in unedited full text through a Regulatory Information Service.
Page numbers and section cross-references in the appendices refer to pages and sections in the Annual Report. Defined terms used in the appendices refer to terms as defined in the Annual Report.
This material is not a substitute for reading the full Annual Report.
APPIX A
The Board has carried out a robust assessment of the Principal Risks facing the Group, including those that threaten its business model, future performance, solvency or liquidity. The table overleaf provides insight into the ongoing Principal Risks, outlining why effective management of these risks is important and relevant to the business, how we are managing them and which risks are rising, falling or have remained static during the past 12 months.
Our approach to risk management is designed to encourage clear decision making on which risks we take and how we manage these risks. Fundamental to this process is a sound understanding of every risk's potential strategic, commercial, financial, compliance, legal and reputational implications.
Further information on our key risk management and assurance processes can be found in Risk from pages 220 to 230 which also includes a description of circumstances under which principal and other risks and uncertainties might arise in the course of our business and their potential impact.
Progress in the delivery of Group-wide restructuring initiatives has been sufficient for the Board to determine that the risk 'Delivery of Gains from Productivity Initiatives' (previously listed as a Principal Risk) is no longer a Principal Risk. The Board will, however, continue to monitor strategic initiatives and their impact on employee engagement.
Hot Features
Premium
Risk category and Principal Context/potential impact Management actions
Risks
Product pipeline and intellectual property
Delivery of pipeline The development of > Prioritise and accelerate
and new products any pharmaceutical our pipeline
product candidate is > Strengthen pipeline
a complex, risky and through acquisitions,
lengthy process involving licensing and collaborations
significant financial, > Focus on innovative
R&D and other resources. science in three main
A project may fail therapy areas
or be delayed at any
stage of the process
due to a number of
factors, which could
reduce our long-term
growth, revenue and
profit.
-------------------------------- -------------------------------
Meet quality, regulatory Our pharmaceutical > Quality management
and ethical drug approval products and commercialisation systems incorporating
and disclosure requirements processes are subject monitoring, training
to extensive regulation. and assurance activities
Delays in regulatory > Collaborating with
reviews and approvals regulatory bodies and
impact patients and advocacy groups to
market access, and monitor and respond
can materially affect to changes in the regulatory
our business or financial environment, including
results. revised process, timelines
and guidance
-------------------------------- -------------------------------
Secure and protect Discovering and developing > Active management
product IP medicines requires of IP rights and IP
a significant investment litigation
of resources. For this
to be a viable investment,
new medicines must
be safeguarded from
being copied for a
reasonable amount of
time. If we are not
successful in obtaining,
maintaining, defending
or enforcing our IP
rights, our revenues
could be materially
adversely affected.
Third parties may allege
infringement of their
IP, and may seek injunctions
and/or damages, which,
if ultimately awarded,
could adversely impact
our commercial and
financial performance.
-------------------------------- -------------------------------
Commercialisation
Externally driven demand, Operating in over 100 > Focus on Growth Platforms
pricing, access and countries, we are subject > Demonstrating value
competitive pressures to political, socioeconomic of medicines/health
and financial factors economics
both globally and in > Global footprint
individual countries. > Diversified portfolio
There can be additional
pressure from governments
and other healthcare
payers on medicine
prices and sales in
response to recessionary
pressures, reducing
our revenue, profits
and cash flow.
-------------------------------- -------------------------------
Quality and execution If commercialisation > Focus on Growth Platforms
of commercial strategies of a product does not > Accelerate and risk
succeed as anticipated, share through business
or its rate of sales development and strategic
growth is slower than collaborations and
anticipated, there alliances
is a risk that we may
not be able to fully
recoup the costs in
launching it.
-------------------------------- -------------------------------
Supply chain and business execution
Maintain supply of Delays or interruptions > Establishment of
compliant, quality in supply can lead new manufacturing facilities,
product to recalls, creating capacity and
product shortages, technical capability
regulatory action, to support new product
reputational harm and launches, particularly
lost sales. biologics
> Business continuity
and resilience initiatives,
disaster and data recovery
and emergency response
plans
> Contingency plans
including dual sourcing,
multiple suppliers
and stock levels
> Quality management
systems
-------------------------------- -------------------------------
Information technology, Significant disruption > Cybersecurity framework
data security and privacy to our IT systems, and dashboard
cybersecurity incidents > Privacy office oversees
including breaches compliance with data
of data security, or privacy legislation
data privacy failure, > Disaster and data
could harm our reputation recovery plans
and materially affect > Strategies to secure
our financial condition critical systems and
or results of operations. processes
This could lead to > Regular cybersecurity
regulatory penalties and privacy training
or non-compliance with for employees
laws and regulations.
-------------------------------- -------------------------------
Attract, develop, engage Failure to attract > Targeted recruitment
and retain talented and retain highly skilled and retention strategies
and capable employees personnel may weaken deployed
at all levels our succession plans > Identification and
for critical positions active support of staff
in the medium term. potentially impacted
Employee uncertainty by Brexit
as a result of, for > Development of our
example, Brexit or employees
organisational change > Evolve our culture
may result in a lower > Focus on simplification
level of employee engagement
which could impact
productivity and turnover.
Both could adversely
affect the achievement
of our strategic objectives.
-------------------------------- -------------------------------
Legal, regulatory and compliance
Safety and efficacy Patient safety is very > Robust processes
of marketed products important to us and and systems in place
we strive to minimise to manage patient safety
the risks and maximise and efficacy trends
the benefits of our as well as externally
medicines. Failure reported risks through
to do this could adversely regulatory agencies
impact our reputation, and other parties.
our business and the This includes a comprehensive
results of operations, pharmacovigilance programme
and could lead to product supplemented by close
liability claims. monitoring and review
of adverse events
-------------------------------- -------------------------------
Defence of product, Investigations or legal > Combined internal
pricing and practices proceedings could be and external counsel
litigation costly, divert management management
attention or damage
our reputation and
demand for our products.
Unfavourable resolutions
could subject us to
criminal liability,
fines, penalties or
other monetary or non-monetary
remedies, adversely
affecting our financial
results.
-------------------------------- -------------------------------
Meet regulatory and Any failure to comply > Strong ethical and
ethical expectations with applicable laws, compliance culture
on commercial practices, rules and regulations, > Established compliance
including bribery and including bribery and framework in place
corruption, and scientific corruption legislation, including annual Code
exchanges may result in civil of Ethics training
and/or criminal legal for all employees
proceedings and/or > Focus on due diligence
regulatory sanctions, and oversight of third-party
fines or penalties, engagements
impacting financial
results.
-------------------------------- -------------------------------
Economic and financial
Achieve strategic plans Failure to successfully > Focus on Growth Platforms
and meet targets and implement our business and innovative science
expectations strategy may frustrate in three main therapy
the achievement of areas
our financial or other > Strengthen pipeline
targets or expectations. through acquisitions,
This failure could, licensing and collaborations
in turn, damage our > Appropriate capital
reputation and materially structure and balance
affect our business, sheet
financial position > Portfolio-driven
or results of operations. decision making process
governed by senior
executive-led committees
-------------------------------- -------------------------------
APPIX B
This statement relates to and is extracted from the Annual Report. It is repeated here solely for the purpose of complying with DTR 6.3.5. It is not connected to the information presented in this announcement or in the Company's fourth quarter and full year results 2018 announcement that was published on 14 February 2019.
The Directors confirm that to the best of our knowledge:
-- The Financial Statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company and the undertakings included in the consolidation taken as a whole.
-- The Directors' Report includes a fair review of the development and performance of the business and the position of the issuer and the undertakings included in the consolidation taken as a whole, together with a description of the principal risks and uncertainties that they face.
On behalf of the Board of Directors on 14 February 2019
Pascal Soriot
Director
APPIX C
Related party transactions
The Group had no material related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.
Media Relations Gonzalo Viña UK/Global +44 203 749 5916 Rob Skelding UK/Global +44 203 749 5821 Matt Kent UK/Global +44 203 749 5906 Jennifer Hursit UK/Global +44 203 749 5762 Christina Malmberg Hägerstrand Sweden +46 8 552 53 106 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris BioPharma - Cardiovascular; Metabolism +44 203 749 5711 Nick Stone BioPharma - Respiratory; Renal +44 203 749 5716 Josie Afolabi Other +44 203 749 5631 Craig Marks Finance; Fixed Income +44 7881 615 764 Jennifer Kretzmann Retail Investors; Corporate Access +44 203 749 5824 US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACSUGUUWWUPBGUA
(END) Dow Jones Newswires
March 05, 2019 06:00 ET (11:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
